Client News

Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board

Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025

Nyxoah Reports First Quarter Financial and Operating Results

Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement

Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program with WEvenamide as Add-On Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Formycon Reports Strong Operational Performance and Financial Results for First Quarter of 2025

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

Galimedix Therapeutics Completes Single Ascending Dose Part of Phase 1 Study with Oral Mmall Molecule, GAL-101, an Amyloid Beta Aggregation Modulator

AFYREN and Südzucker Celebrate 5 Years of Strategic Bioeconomy Partnership

InflaRx to Report First Quarter 2025 Results on May 7, 2025